dc.contributor.author | Chojnacki, Cezary | |
dc.contributor.author | Popławski, Tomasz | |
dc.contributor.author | Blasiak, Janusz | |
dc.contributor.author | Chojnacki, Jan | |
dc.contributor.author | Gasiorowska, Anita | |
dc.date.accessioned | 2021-11-08T13:51:57Z | |
dc.date.available | 2021-11-08T13:51:57Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Chojnacki C, Popławski T, Gasiorowska A, Chojnacki J, Blasiak J. Serotonin in the Pathogenesis of Lymphocytic Colitis. Journal of Clinical Medicine. 2021; 10(2):285. https://doi.org/10.3390/jcm10020285 | pl_PL |
dc.identifier.uri | http://hdl.handle.net/11089/39708 | |
dc.description.abstract | Lymphocytic colitis (LC) is a chronic inflammatory disease associated with watery diarrhea, abdominal pain, and colonic intraepithelial lymphocytosis. Serotonin (5-hydroxytryptamine, 5-HT) is reported to increase in certain colon diseases; however, little is known regarding its metabolism in LC. In the present work, the level of 5-HT in serum and the number of enteroendocrine cells (EECs) as well as the expression of the 5-HT rate-limiting enzyme tryptophan hydroxylase 1 (TPH1) in colonic biopsies and urine 5-hydroxyindoeoacetic acid (5-HIAA) were determined in 36 LC patients that were treated with budesonide and 32 healthy controls. The 5-HT serum and 5-HIAA urine levels were measured using ELISA, the EEC number was determined immunohistochemically, and the colonic TPH1 mRNA expression was determined using RT-PCR. The levels of 5-HT and 5-HIAA and the number of EECs were higher in LC patients than in the controls, and positive correlations were observed between the 5-HT and 5-HIAA levels, 5-HT and EEC number, TPH1 mRNA and EEC number, as well as the severity of disease symptoms and 5-HIAA. Budesonide decreased the levels of 5-HT, 5-HIAA, and TPH1 expression and the number of EECs to values that did not differ from those for controls. In conclusion, the serotonin metabolism may be important for LC pathogenesis, and the urinary level of 5-HIAA may be considered as a non-invasive marker of this disease activity. | pl_PL |
dc.description.sponsorship | This research was funded by the Medical University of Lodz, grant number 503/6-006-0. | pl_PL |
dc.language.iso | en | pl_PL |
dc.publisher | MDPI | pl_PL |
dc.relation.ispartofseries | Journal of Clinical Medicine;10(2) | |
dc.rights | Uznanie autorstwa 4.0 Międzynarodowe | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | lymphocytic colitis | pl_PL |
dc.subject | enteroendocrine cells | pl_PL |
dc.subject | tryptophan hydroxylase | pl_PL |
dc.subject | serotonin | pl_PL |
dc.subject | 5-hydroxyindoleacetic acid | pl_PL |
dc.subject | budesonide | pl_PL |
dc.title | Serotonin in the Pathogenesis of Lymphocytic Colitis | pl_PL |
dc.type | Article | pl_PL |
dc.page.number | 10 | pl_PL |
dc.contributor.authorAffiliation | Department of Clinical Nutrition and Gastroenterological Diagnostics, Medical University of Lodz, 90-647 Lodz, Poland | pl_PL |
dc.contributor.authorAffiliation | Department of Molecular Genetics, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland | pl_PL |
dc.contributor.authorAffiliation | Department of Molecular Genetics, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland | pl_PL |
dc.contributor.authorAffiliation | Department of Clinical Nutrition and Gastroenterological Diagnostics, Medical University of Lodz, 90-647 Lodz, Poland | pl_PL |
dc.contributor.authorAffiliation | Department of Gastroenterology, Medical University of Lodz, 90-647 Lodz, Poland | pl_PL |
dc.identifier.eissn | 2077-0383 | |
dc.references | Miehlke, S.; Verhaegh, B.; Tontini, G.E.; Madisch, A.; Langner, C.; Münch, A. Microscopic colitis: Pathophysiology and clinical management. Lancet Gastroenterol. Hepatol. 2019, 4, 305–314. | pl_PL |
dc.references | Bonderup, O.K.; Wigh, T.; Nielsen, G.L.; Pedersen, L.; Fenger-Grøn, M. The epidemiology of microscopic colitis: A 10-year pathology-based nationwide Danish cohort study. Scand. J. Gastroenterol. 2015, 50, 393–398 | pl_PL |
dc.references | Williams, J.J.; Kaplan, G.G.; Makhija, S.; Urbanski, S.J.; Dupre, M.; Panaccione, R.; Beck, P.L. Microscopic Colitis–Defining Incidence Rates and Risk Factors: A Population-Based Study. Clin. Gastroenterol. Hepatol. 2008, 6, 35–40 | pl_PL |
dc.references | Guagnozzi, D.; Lucendo, A.J. Advances in knowledge on microscopic colitis: From bench to bedside. Revista Española de Enfermedades Digestivas 2015, 107, 98–108 | pl_PL |
dc.references | Münch, A.; Aust, D.; Bohr, J.; Bonderup, O.; Bañares, F.F.; Hjortswang, H.; Madisch, A.; Munck, L.; Strom, M.; Tysk, C.; et al. Microscopic colitis: Current status, present and future challenges. J. Crohn’s Colitis 2012, 6, 932–945. | pl_PL |
dc.references | Fiehn, A.-M.K.; Engel, U.; Holck, S.; Munck, L.K.; Engel, P.J.H. CD3 immunohistochemical staining in diagnosis of lymphocytic colitis. Hum. Pathol. 2016, 48, 25–31. | pl_PL |
dc.references | Chetty, R.; Govender, D. Lymphocytic and collagenous colitis: An overview of so-called microscopic colitis. Nat. Rev. Gastroenterol. Hepatol. 2012, 9, 209–218. | pl_PL |
dc.references | Ahmad, O.F.; Akbar, A. Overview of microscopic colitis. Br. J. Hosp. Med. 2020, 81, 1–7 | pl_PL |
dc.references | Borsotti, E.; Barberio, B.; D’Incà, R.; Bonitta, G.; Cavallaro, F.; Spina, L.; Pastorelli, L.; Rondonotti, E.; Samperi, L.; Dinelli, M.; et al. Low prevalence of colorectal neoplasia in microscopic colitis: A large prospective multi-center study. Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver 2020. | pl_PL |
dc.references | Chojnacki, J.B.C.; Błasiak, J.; Fichna, J.; Chojnacki, J.; Popławski, T.; Zielioski, K. Evaluation of the Extrapineal Sources of Melatonin in Patients with Lymphocytic Colitis. Int. J. Multidiscip. Curr. Res. 2017, 6, 857–863. | pl_PL |
dc.references | El-Salhy, M.; Gundersen, D.; Hatlebakk, J.G.; Hausken, T. Chromogranin A Cell Density as a Diagnostic Marker for Lymphocytic Colitis. Dig. Dis. Sci. 2012, 57, 3154–3159. | pl_PL |
dc.references | El-Salhy, M.; Gundersen, R.; Hatlebakk, J.G.; Hausken, T. High densities of serotonin and peptide YY cells in the colon of patients with lymphocytic colitis. World J. Gastroenterol. 2012, 18, 6070–6075. | pl_PL |
dc.references | Gershon, M.D.; Tack, J. The serotonin signaling system: From basic understanding to drug development for functional GI disorders. Gastroenterology 2007, 132, 397–414. | pl_PL |
dc.references | Mawe, G.M.; Hoffman, J.M. Serotonin signalling in the gut—Functions, dysfunctions and therapeutic targets. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 473–486. | pl_PL |
dc.references | Coates, M.D.; Mahoney, C.R.; Linden, D.R.; Sampson, J.E.; Chen, J.; Blaszyk, H.; Crowell, M.D.; Sharkey, K.A.; Gershon, M.D.; Mawe, G.M. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome 1. Gastroenterology 2004, 126, 1657–1664. | pl_PL |
dc.references | Côté, F.; Thévenot, E.; Fligny, C.; Fromes, Y.; Darmon, M.; Ripoche, M.-A.; Bayard, E.; Hanoun, N.; Saurini, F.; Lechat, P.; et al. Disruption of the nonneuronal tph1 gene demonstrates the importance of peripheral serotonin in cardiac function. Proc. Natl. Acad. Sci. USA 2003, 100, 13525–13530 | pl_PL |
dc.references | Walther, D.J.; Peter, J.U.; Bashammakh, S.; Hörtnagl, H.; Voits, M.; Fink, H.; Bader, M. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003, 299, 76. | pl_PL |
dc.references | Chojnacki, C.; Popławski, T.; Chojnacki, J.; Fila, M.; Konrad, P.; Blasiak, J. Tryptophan intake and metabolism in older adults with mood disorders. Nutrients 2020, 12, 3183. | pl_PL |
dc.references | Thijssen, A.Y.; Mujagic, Z.; Jonkers, D.M.; Ludidi, S.; Keszthelyi, D.; Hesselink, M.A.; Clemens, C.H.M.; Conchillo, J.M.; Kruimel, J.W.; Masclee, A.A.M. Alterations in serotonin metabolism in the irritable bowel syndrome. Aliment. Pharmacol. Ther. 2015, 43, 272–282. | pl_PL |
dc.references | Lund, M.L.; Egerod, K.L.; Engelstoft, M.S.; Dmytriyeva, O.; Theodorsson, E.; Patel, B.A.; Schwartz, T.W. Enterochromaffin 5-HT cells—A major target for GLP-1 and gut microbial metabolites. Mol. Metab. 2018, 11, 70–83. | pl_PL |
dc.references | Delgado, D.A.; Lambert, B.S.; Boutris, N.; McCulloch, P.C.; Robbins, A.B.; Moreno, M.R.; Harris, J.D. Validation of digital visual analog scale pain scoring with a traditional paper-based visual analog scale in adults. JAAOS Glob. Res. Rev. 2018, 2, e088. | pl_PL |
dc.references | Schmittgen, T.D.; Livak, K.J. Analyzing real-time PCR data by the comparative CT method. Nat. Protoc. 2008, 3, 1101–1108. | pl_PL |
dc.references | Tong, J.; Zheng, Q.; Zhang, C.; Lo, R.; Shen, J.; Ran, Z. Incidence, prevalence, and temporal trends of microscopic colitis: A systematic review and meta-analysis. Am. J. Gastroenterol. 2015, 110, 265–276. | pl_PL |
dc.references | Wan, M.; Ding, L.; Wang, D.; Han, J.; Gao, P. Serotonin: A potent immune cell modulator in autoimmune diseases. Front. Immunol. 2020, 11, 11 | pl_PL |
dc.references | Jørandli, J.W.; Thorsvik, S.; Skovdahl, H.K.; Kornfeld, B.; Sæterstad, S.; Gustafsson, B.I.; Sandvik, A.K.; Granlund, A.V.B. The ser-otonin reuptake transporter is reduced in the epithelium of active Crohn’s disease and ulcerative colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2020. | pl_PL |
dc.references | Kwon, Y.H.; Wang, H.; Denou, E.; Ghia, J.-E.; Rossi, L.; Fontes, M.E.; Bernier, S.P.; Shajib, S.; Banskota, S.; Collins, S.M.; et al. Modulation of Gut Microbiota Composition by Serotonin Signaling Influences Intestinal Immune Response and Susceptibility to Colitis. Cell. Mol. Gastroenterol. Hepatol. 2019, 7, 709–728. | pl_PL |
dc.references | Fernández-Bañares, F.; Esteve, M.; Espinós, J.C.; Rosinach, M.; Forné, M.; Salas, A.R.; Viver, J.M. Drug consumption and the risk of microscopic colitis. Am. J. Gastroenterol. 2007, 102, 324–330. | pl_PL |
dc.references | Lucendo, A.J. Drug exposure and the risk of microscopic colitis: A critical update. Drugs R&D 2017, 17, 79–89. | pl_PL |
dc.references | Khan, W.I. The role of 5-HT dysregulation in inflammatory Bowel Disease. Gastroenterol. Hepatol. 2013, 9, 259–261. | pl_PL |
dc.references | Miehlke, S.; Aust, D.E.; Mihaly, E.; Armerding, P.; Böhm, G.; Bonderup, O.K.; Fernández-Bañares, F.; Kupcinskas, J.; Munck, L.K.; Rehbehn, K.-U.; et al. Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis. Gastroenterology 2018, 155, 1795–1804.e3. | pl_PL |
dc.references | Townsend, T.; Campbell, F.; O’Toole, P.; Probert, C. Microscopic colitis: Diagnosis and management. Front. Gastroenterol. 2019, 10, 388–393 | pl_PL |
dc.references | Dey, I.; Beck, P.L.; Chadee, K. Lymphocytic Colitis Is Associated with Increased Pro-Inflammatory Cytokine Profile and Up Regulation of Prostaglandin Receptor EP4. PLoS ONE 2013, 8, e61891. | pl_PL |
dc.references | Pisani, L.F.; Tontini, G.E.; Marinoni, B.; Villanacci, V.; Bruni, B.; Vecchi, M.; Pastorelli, L. Biomarkers and Microscopic Colitis: An Unmet Need in Clinical Practice. Front. Med. 2017, 4, 54. | pl_PL |
dc.references | Chojnacki, C.; Blasiak, J.; Fichna, J.; Chojnacki, J.; Popławski, T. Evaluation of Melatonin Secretion and Metabolism Exponents in Patients with Ulcerative and Lymphocytic Colitis. Molecules 2018, 23, 272. | pl_PL |
dc.references | Gershon, M.D. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr. Opin. Endocrinol. Diabetes Obes. 2013, 20, 14–21. | pl_PL |
dc.references | Brown, P.M.; Drossman, U.A.; Wood, A.J.J.; Cline, G.A.; Frazier, K.S.; Jackson, J.I.; Bronner, J.; Freiman, J.; Zambrowicz, B.; Sands, A.; et al. The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome. Gastroenterology 2011, 141, 507–516. | pl_PL |
dc.references | Kritas, S.K.; Saggini, A.; Cerulli, G.; Caraffa, A.; Antinolfi, P.; Pantalone, A.; Rosati, M.; Tei, M.; Speziali, A.; Saggini, R.; et al. Re-lationship between serotonin and mast cells: Inhibitory effect of anti-serotonin. J. Biol. Regul. Homeost. Agents 2014, 28, 377–380. | pl_PL |
dc.references | Münch, A.; Bohr, J.; Miehlke, S.; Benoni, C.; Olesen, M.; Öst, Å.; Strandberg, L.; Hellström, P.M.; Hertervig, E.; Armerding, P.; et al. Low-dose budesonide for maintenance of clinical remission in collagenous colitis: A randomised, placebo-controlled, 12-month trial. Gut 2016, 65, 47–56. | pl_PL |
dc.identifier.doi | 10.3390/jcm10020285 | |
dc.relation.volume | 285 | pl_PL |
dc.discipline | nauki biologiczne | pl_PL |